SetPoint Medical Corp Overview
Pro stress-test →SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with autoimmune diseases through a novel platform designed to stimulate the vagus nerve to activate innate anti-inflammatory pathways to produce a systemic immune-restorative effect. The company achieved a major milestone in July 2025 when the U.S. Food and Drug Administration (FDA) approved the company's SetPoint System, a breakthrough innovation for people with rheumatoid arthritis (RA).
Strategic Profile
Pro stress-test →The SetPoint System is the first neuroimmune modulation therapy available for people living with rheumatoid arthritis (RA), offering a novel, device-based alternative for those who do not respond to or cannot tolerate biologic or targeted drug therapies. In March 2024, SetPoint received breakthrough device designation from the FDA for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS). The company is expanding its addressable market beyond RA into other chronic autoimmune conditions.
Competitive Landscape
Pro stress-test →Competitors include Salvia BioElectronics, Mainstay Medical, Saluda Medical, Aleva Neurotherapeutics, and Curonix. SetPoint differentiates through its first-in-class FDA approval for neuroimmune modulation addressing a significant unmet need in RA treatment, where only 25% of RA patients are satisfied with their therapy and up to 50% discontinue their prescribed therapies within two years. The company's platform approach allows potential expansion into multiple autoimmune conditions.
Industry Context
SetPoint Medical Corp operates in Implantable neuromodulation medical devices.
Key facts
Headquarters: Valencia, CA, US · Employees: 90